1

Audrey’s Life Science Meeting Picks for May 22, 2016 – August 2016

Complimentary Service of AudreysNetwork.com

May 22, 2016

**********************************************************************

Bio2Device Group, Tuesday Morning, May 24, 2016

Topic: “Green Chemistry Global Adoption: Its challenges, advances and opportunities”

Speakers: Neelam Vaidya and Jose Castanon , CEO and Marketing Executive, ViridisChem Inc.

Date and Time: Tuesday, May 24, 2016, 8:30 am

Location: Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale

There is no registration or fee required for morning meetings.

Topic Description

In 2014, Neelam and Rahul Vaidya cofounded ViridisChem Inc. with the mission to develop a

portfolio of software solutions that will provide all the information and analysis capabilities

scientists would need to practice “green chemistry” within their everyday research, that will

result in environmentally friendly product development processes that are greener, safer, and

economical. To enable this goal, the company has built in-house and proprietary

- chemical database with over 60 million chemicals,

- citation database with over 20 million citations and patents,

- reaction database with over 10 million reference reactions

It recently launched its first product Green Pocketbook that is being used both as an educational

tool and as a reference guide by universities and industry scientists for their day-to-day research

needs. It provides full chemical and toxicological profiles of chemicals, and offers “green

scores” based on these properties through easy to understand visual charts. With inclusion of

chemicals relevant to most industries, and by providing the most comprehensive information

about chemicals in a very easy to use and understand manner, Green Pocketbook is proving to be

a “must have” software solution for scientists from most industries for their day-to-day work.

During this 1-hour interactive session, the presenters will discuss:

- Green Chemistry Global Revolution: What is it, when did it start? Why is there a global and

mandatory adoption enforced by the governments?

- Current status and advances by different industries

- Roadblocks that are stopping companies from adopting green-aware research

- Challenges and Opportunities and solutions available today

- Specific needs of different industries and how are we addressing them?

- ViridisChem Solutions

- Issues surrounding “green data” and “green scores” and relationship between toxicological data

and green scores

- Green Pocketbook Product Demo

Speaker Bios

2

Neelam Vaidya is a serial entrepreneur with over 25 years’ experience in both high-tech and bio-

tech industry. In past she was the founder and CEO of a biotech company ChiroSolve, Inc. that

offers products and services that define chiral resolution method for optically active and hard-to-

separate chiral molecules. Neelam was also the founder of Software Company called Perfect

Solutions that offered enterprise software products for high-tech industry. Before her

entrepreneur career, Neelam has lead number high-profile enterprise infrastructure projects at

companies like Sun Microsystems, IBM, NASA, etc. She has M.S. in Computer Science and

B.S. in Chemistry.

Jose Castanon is a marketing professional with over 15 years of experience in medical

technology and devices. He specializes in growth strategies and bringing new technologies to

market. Prior to ViridisChem Jose was the Director of Marketing for Omnicell, where he led all

North American marketing activity for the Medication Automation and Analytics business line.

Jose has held commercial leadership roles at Philips Healthcare, Roche and Johnson and

Johnson. He holds a BS in Biology from the University of Puget Sound and an MBA from

Pepperdine University. *************************************************************

BioScience Forum, Wednesday Evening, May 25, 2016

Topic: "Recent Trends in the Biopharma Financing and Licensing Market"

Speaker: Chris Ehrlich, Managing Director , Locust Walk Partners

Date and Time: Wednesday, May 25, 2016 6:00 PM - 9:00 PM

Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA

6 pm - 7 pm networking

7 pm - 8 pm dinner

8 pm - 9 pm presentation

Event Registration ($3 service fee will apply)

Pre-Registration $50.00

On-Site Registration $60.00

Pre-Registration ends Monday, May 23rd, at 9 pm

Cash or check accepted on the day of the event

$10 discount for full-time students

Register at https://www.cvent.com/events/bioscience-forum-chris-ehrlich-locust-walk-

partners/registration-3a0bf21203ee4b368d1cda29b7ff1bc5.aspx

Or you can pay with a check made out to "BioScience Forum" and sent to:

BioScience Forum

1442A Walnut Street, #308

Berkeley, CA 94709-1405

Please do not mail checks later than Thursday, May 19th

If paying with check, do not complete online registration with Cvent

Topic Description

Three years of strong financial performance in healthcare have generated over $50 billion in

potential value back to investors. Last year saw the most capital invested in healthcare

companies compared to any other year. The key driver in this performance, record

investment in biopharma, saw the largest share of crossover investment by non-traditional

biotech investors participating in large mezzanine rounds. The past three years have also

seen the largest sustained and most prosperous IPO bull market in healthcare, but the IPO

markets have dipped in the beginning of the new year.

When public markets taper off, we start to see spikes elsewhere, such as in partnering

activities. Total M&A deal values have reached a decade-high, and partnering deals spiked

3

both in number and value toward the end of 2015 into 2016. Licensing deals have also seen

an upward trend in value, with up-front payouts increasing for large and small deals alike.

The overall outlook for biopharma is positive, as these exits and successes have led to

higher returns and greater investor confidence. Timely and successful fundraising cycles

mean venture healthcare has enough capital to support existing investments and new

financings, which will reinforce biotech companies as the IPO market declines and non-

traditional crossover investors pull away.

Chris Ehrlich will analyze these and other key trends and data from 2015 in the financing

and licensing markets of biopharma, and provide his outlook on the opportunities and

challenges the biotechnology industry is facing in 2016.

Speaker Bio

Chris Ehrlich is a Managing Director and Head of the West Coast office for Locust Walk

Partners. He has significant biotechnology industry and venture capital experience. Since

joining Locust Walk in 2013, Chris has been involved with leading multiple transactions for

emerging biopharmaceutical companies.

Prior to Locust Walk, he was a Managing Director at InterWest Partners. He previously

served on the boards of KAI Pharmaceuticals as the Lead Director (acquired by Amgen),

Biomimetic Therapeutics, Inc. (acquired by Wright Medical Technologies) and Xenon

Pharmaceuticals. He was also a founder and board member of Carbylan Therapeutics. At all

four companies, he sat on the Transaction Committees of the Board of Directors where he

oversaw numerous business development deals.

Prior to joining InterWest, Ehrlich was director, licensing and business development at

Purdue Pharma, a private pharmaceutical firm based in Stamford, CT where he was

responsible for developing a biologic oncology franchise.

Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture

capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at

LEK Consulting.

He has an undergraduate degree, cum laude, from Dartmouth College and an MBA from the

Kellogg School of Management at Northwestern University.

He currently serves on the Board of Directors of Prostate Management Diagnostics, Inc. and

on the Advisory Boards of Innovations and New Ventures at Northwestern University and

the Peter Michael Foundation, where he is a Senior Advisor. He is also a member of the

Young Presidents Organization.

He is a registered rep with FINRA, holding both his Series 79 and 63 licenses.

********************************************************************

HBA, Thursday Evening, May 26, 2016

Event: “HB8 Dine-Around: The State of International Women's Health Today with Sally

Stephens”

Featured speaker

Sally Stephens

Senior vice president, corporate development, Medicines360

Date and Time: Thursday, May 26, 2016

4

5:30 - 6:15 PM Networking and appetizers 6:15 - 6:30 PM HBA welcome 6:30 - 7:15 PM Dinner and discussion led by Sally Stephens 7:15 - 8:00 PM Q&A discussion, dessert and networking Location: Giant Creative Agency, 1700 Montgomery Street #485, San Francisco, CA 94111 Registration information Event is open to: HBA members only Online registration deadline: May 24, 2016 Onsite (walk-in) registration: Is NOT allowed Member rate: $35 until May 18, 2016 $45 after May 18, 2016 Space is limited to 20 registrants. Cancellations/refunds Is this event refundable? Yes If yes, requests must be submitted in writing to events@hbanet.org by May 24, 2016; no refunds are available after this date. Registration and information at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=1EC2240B-52F8-E511-998D-0050569C00A7

Event Description

May 8 - 14 is National Women's Health Week. As the department of health and human

services and organizations rally to help US women understand the steps they can take to

improve their health, it's hard to not think about the majority of women internationally who

lack access to the basic health services we take for granted in our own county.

Did you know?:

• The number of women worldwide who had an unmet need for modern contraception

in 2012 was 222 million

• In Africa, only 29 percent of women of reproductive age use modern contraception

and the average number of children per woman is 4.7

• 40 percent of girls in sub-Saharan Africa are married before the age of 18

• There are 1.8 billion young people in the world right now (ages 10-24)... 600 million

are adolescent girls. Never before has there been so many young people.

Join us for an engaging dinner discussion with Sally Stephens, senior vice president,

corporate development at Medicines360, as we take a look at the state of women's health

globally. For organizations like Medicines360, whose mission is to expand access to

medicines for women regardless of their socioeconomic status, insurance coverage or

geographic location, the key is to innovate on many different levels in order to meet the still

unmet need in global women's health today.

**************************************************************

WIB Webinar, Thursday Afternoon, May 26, 2016

National Webinar: “Raising Capital for Rising Companies”

Heather Smith, Managing Director, Head of Private Financing Solutions, Sagent Advisors

Date and Time: Thursday, May 26, 2016

1:00 p.m. – 1:45 p.m. EST Presentation by Heather Smith

1:45 p.m. – 2:00 p.m. EST Q&A

Pricing Information

Members: Free

Non-Members: $15

5

Registration Deadline

May 25, 2016

Register at http://www.womeninbio.org/eventdetails.aspx?EventId=28822

Webinar Description

Regardless of whether one works in industry or academia, each of us plays a role in the

financial health of our organizations. From grant writing to private equity funding, there are

reasons behind the success of those who secure the funding.

Join us as Heather Smith, Managing Director, Head of Private Financing Solutions, Sagent

Advisors, discusses healthcare and technology trends and forecasts, as well as provides

insights into successful financing strategies. Heather will also discuss what makes a good

solid business, and what we need to know about market trends that impacts all of us - from

payer payments, adoption and approval processes, and reimbursements. Attendees will

have the opportunity for Q&A at the end of the presentation to have their questions

answered directly by Ms. Smith.

Speaker Bio

Heather leads the firm’s Private Financing Solutions practice. She has over 19 years of

experience in the equity and debt private placement industry, raising approximately $12

billion in private placements for companies in the U.S., Europe, South America and Asia.

Before joining Sagent, Heather was a Partner and Head of Private Placements at Greentech

Capital Advisors where she originated, structured and placed equity, mezzanine and senior

debt capital for domestic and international private companies in the sustainability sector,

including a $1.25 billion equity and project financing for GreatPoint Energy and a €463

million recapitalization and growth financing for agri.capital. Before Greentech Capital

Advisors, Ms. Smith was the Head of the Structured Private Placement Group at Deutsche

Bank Securities, Inc. raising significant equity and mezzanine capital for private companies

utilizing highly complex, customized financing structures. Prior to founding the Structured

Private Placements Group at Deutsche Bank, she was a Director and Chief Operating Officer

for the Private Placement Group at Credit Suisse Securities and Donaldson, Lufkin and

Jenrette. While at Credit Suisse / DLJ, she was fundamental in raising equity and/or

mezzanine for over 100 clients. Prior to working at CS, she was in the Private Placement

Group at Prudential Securities. She began her career at First Chicago Corporation (now part

of J.P. Morgan) where she was selected to participate in a multi-year management

executive training program and traded Foreign Exchange forward, options and futures.

Heather received her Master of Business Administration degree in Finance, International

Studies and Marketing with distinction from J.L. Kellogg Graduate School of Management at

Northwestern University and her Bachelor of Arts degree, cum laude, in Economics from

Harvard University.

**************************************************************

Rosenman Institute, Thursday Early Evening, May 26, 2016

Topic: “D-Series:How to Commercialize and Scale Your Product for Global Health Markets”

Speaker: Krista Donaldson, CEO of D-Rev. "Brilliance,"

Date and Time: Thursday, May 26, 2016

5:00-6:00 pm Sign-in & reception

6:00-7:00 pm Talk and Q&A

Location: UCSF Mission Bay, Byers Hall, Second Floor "Library"

Space is limited.

Fee: General - $10

6

Register at http://www.eventbrite.com/e/d-series-krista-donaldson-d-rev-how-to-

commercialize-and-scale-your-product-for-global-health-tickets-

25241228193?mc_cid=6af28609b2&mc_eid=cb4c38a44a

Topic Description

The D-Series is our forum on medical device development in the Bay Area. Join us to learn

about the latest technology and meet leaders in the field.

Bringing a device to the US market is challenging. But if you’re developing a solution for

patients around the world, the challenge is even bigger. Join us to hear from Krista

Donaldson, CEO of D-Rev. "Brilliance," D-Rev's phototherapy device for severely jaundiced

newborns, has helped doctors in 40 countries treat more than 130,000 babies. Krista will

discuss how D-Rev is developing new products based on the lessons learned

commercializing and scaling Brilliance.

Speaker Bio

Krista Donaldson, PhD, has driven innovation in product design, engineering, and

international development for more than 15 years. As D-Rev’s CEO, Krista’s has led the

release of Brilliance, a revolutionary technology treating neonatal jaundice, and the

ReMotion prosthetic knee. Her leadership has won Krista acclaim as one of Fast Company’s

Co.Design 50 Designers Shaping the Future, a TED speaker and a World Economic Forum

Technology Pioneer. She has also been a Rainer Arnhold Fellow and a Pop!Tech Social

Innovation Fellow.

***********************************************************

Bio2Device Group, Tuesday Morning, May 31, 2016

Topic: “How to Take a Medical Device from Concept to Market Without Losing Your Shirt “

Speaker: John N. Hendrick ,President & CEO, Mynosys

Date and Time: Tuesday, May 31, 2016, 8:30 am

Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA

There is no registration or fee required for morning meetings.

Speaker Bio

John Hendrick has over three decades of executive experience, building both early stage

medical device companies as well as large divisions in Medical device Corporations.

During his tenure, Mr. Hendrick has participated in the development, manufacture and sales

of products in the field of Cardiology, Urology, Orthopedics and Ophthalmology.

Currently, Mr. Hendrick is president and CEO of Mynosys Cellular Devices an ophthalmic

company. Previously he was CEO of NeoVista Inc. a company in the field of Age Related

Macular Degeneration. Prior to his accepting the role of CEO with Neovista, he created the

Medical Division of Sanmina-Sci, a $12 billion dollar contract manufacturing corporation

bringing the sales of the division from 200 million to over 6oo million in two years becoming

the largest medical device contract manufacturer in world. Mr. Hendrick has been through a

successful IPO of VidaMed which led eventually to the acquisition of the Company by

Medtronic Inc. Prior to VidaMed, Mr. Hendrick held executive positions in Allergan Medical

Optics, Baxter and American Hospital Supply along with several board positions.

Currently Mr. Hendrick serves on the board of Mynosys cellular Devices Inc. as well as

advisor to Lutronic.

*******************************************************

PBSS, Tuesday Afternoon, May 31, 2016 T

Event Type: Workshop Workshop: ”Pharmacology animal models in drug development:

fundamentals, applications and case studies related to oncology, metabolic diseases,

7

inflammation and immunology”

Speakers: Dirk Mendel (E-Scape Bio), Stephen Gould (Genentech), Rana Samadfam

(Charles River Laboratories), Peter Havel (UC Davis), Leon Hall (Mousera)

Date and Time: Tuesday, May 31, 2016, 12:30-17:00

Location: SF Bay Area: Foster City Crowne Plaza

Registration fee (US$): Regular: $125; For vendor-show reps: $25; For unemployed &

students: $20; For major-sponsor rep (incl lunch): $0; For others, details available upon

online login.

Registration: http://www.PBSS.org

Further Information:

Registration deadline: 5/27/2016 (it will close sooner if the seating cap is reached)

********************************************************************

Clinovo Bio Talks, Wednesday Evening, June 1, 2016

Topic: "Setting up Early Stage Clinical Trials".

Date and Time: Wednesday, June 1, 2016, 6: 00 pm

Location: Hewlett Packard, Palo Alto

As always, food and wine provided :)

Register for free at: http://tinyurl.com/jnrteve*

Topic Description

I am happy to announce that registration for the next Silicon Valley BioTalks is now open.

Experts from Hallux, Apexigen, Experien Group and ClinCapture will explore some of the

challenges small and start-up biotechs face when launching clinical development programs.

This will be the 12th session of our BioTalks Chapter! **********************************************************

South Bay HBA, Saturday, June 4, 2016

Event: South Bay Coffee Chat

Location: Shoreline Lake American Bistro - 3160 N Shoreline Blvd., Mountain View, CA

To RSVP or for more information, please contact Meggin Taylor or Mary Dosunmu

*************************************************************************

BIO International Conference, June 6 – 9, 2016

Dates: June 6 – 9, 2016

Location: Moscone Convention Center, North, South and West Halls

Fees: Convention Access - $1,200, Members and 1,450, Non Members before April 16;

$1,400, Members and $1,750 for nonmembers after April 16 (see other package pricing at

http://convention.bio.org/register/)

*****************************************************************

WIB, Monday Afternoon, June 6, 2016

Topic: Women in Bio Plenary Event at BIO Convention: “The Influential Paths of Great

Visionary Leaders”

Speakers include: Firelli Alonso, Senior Director, Biotherapeutics and Vaccines Outsourcing,

Pfizer; Lisa Cohen, Executive Director, Washington Global Health Alliance; Renee Compton

Ryan, Vice President, Venture Investments, Johnson & Johnson; Bahija Jallal, Executive Vice

President, AstraZeneca, Head of MedImmune

Date and Time: Monday, June 6, 2016, 4:00 – 7:00 pm

Location: Clift Hotel, 495 Geary Street San Francisco, CA, 94102

8

Walk-Ins Accepted?

Yes*

* - Walk-ins will be accepted at the door until event capacity is reached.

Pricing Information

Members

Early bird rate through May 6, 2016: $60

Regular rate through June 2, 2016: $80

Late/walk-in rate beginning June 3, 2016*: $100

Non-Members

Early bird rate through May 6, 2016: $90

Regular rate through June 2, 2016: $110

Late/walk-in rate beginning June 3, 2016*: $130

* - Late/walk-in pricing will be effective at the door on-site.

On-Line Registration Deadline

June 3, 2016

Register at http://www.womeninbio.org/eventdetails.aspx?EventId=28587

Topic Description

In conjunction with the Biotechnology Innovation Organization (BIO) International

Convention, please join us for our signature annual WIB Plenary Event on Monday, June 6,

2016, at the beautiful Clift Hotel. Our panel of esteemed speakers will discuss critical, and

often controversial, issues affecting women in the life sciences industry, identify important

industry trends and how to act on them, and how they created their career paths. This

panel is sure to inspire and motivate both women and men to work together to support the

career development of women!

Date and Time: Monday, June 6, 2016, 4:00 – 6:00 pm

As with all WIB events, our Plenary Event encompasses an inviting and fun environment for

networking as it brings together people from all corners of the life sciences industry, and

spawns new career and business opportunities.

This event is not to be missed so register today!

*****************************************************************

BIO Career Fair, Thursday Afternoon, June 9, 2016

Event: BIO Career Fair

Date and Time: Thursday, June 9, 2016, 2:00 – 7:00 pm

Cost: Free

Details and registration at http://convention.bio.org/careerfair-jobseekers/

BIO is proud to announce the 2016 BIO Career Fair, Thursday June 9 from 2:00 - 7:00 pm.

As an extension of BIO’s online job board—Bio Jobs—the Career Fair will provide an

opportunity for meeting participants and top employers to discuss career opportunities..

The BIO Career Fair (is free) and will allow you access to many of the world’s leading life

science companies. A minimum of a 4-year life science degree OR a community college

biotech degree is recommended and military veterans are encouraged to apply. Details at

More information coming soon!

*********************************************************************

qb3, Thursday MidDay, June 9, 2016

Register now for the QB3 Spring 2016 NSF SBIR Bootcamp

UCSF Mission Bay

Two one-hour classes. Location: Genentech Hall N-114, UCSF Mission Bay

First session: Thursday, May 5

Second session: Thursday, June 9

9

Please note that this workshop will exclusively focus on the specifics of the NSF

application and will not cover the basic information covered in our longer course. For

this reason, we recommend that you sign up for this session if you have previously

attended the QB3 NIH SBIR workshop or have a basic understanding of the SBIR

process.

Our NSF SBIR/STTR workshop will address specific differences between the NSF and

NIH applications to successfully file a well-written SBIR/STTR grant application for

the June 16 NSF SBIR deadline (June 20 for STTRs). The course culminates in a

submission clinic that will ensure your application is correctly filed.

One or more team members from the company should be prepared to attend every

session.

Remember to bring your laptop; these will be working sessions.

Course includes

One 1-hour working session, plus one 1-hour filing clinic

Pre-submission review of specific aims by our course instructors

Session 1 will cover the application process, including registration

Session 2 will cover the upload and submission process

Schedule

Dates Time Location

5/5 (Thurs) 1:00-2:00 PM Room N-114, Genentech Hall

6/9(Thurs) 1:00-2:00 PM Room N-114, Genentech Hall

Instructor: Shauna Farr-Jones, PhD, UCSF/QB3 grant writer

Standard rate for the entire workshop: $150 per company

Discounted rate for UC affiliates, QB3 Startup in a Box members, QB3 Incubator

members, and QB3/CLSA Accelerator members: $50 for entire course per company

Teams registered for the Spring 2016 QB3 NIH SBIR workshop: $0

Have questions about QB3 Spring 2016 NSF SBIR Bootcamp? Contact QB3

*********************************************************************

HPLC, Sunday, June 19, 2016

Topic: “HPLC 2016 - 44th International Symposium and Exhibit on High Performance Liquid

Phase Separations and Related Techniques”

Date and Time: Sunday, June 19, 2016 , 8:30 am

Location: Mariott San Francisco Marquis

The goal of HPLC 2016 is to bring together scientists who use and develop

HPLC, capillary electrophoresis, supercritical fluidic chromatography, microfluidics, and mass

spectrometry to exchange ideas, best practices, and

latest developments. The conference program is guided by emerging trends in

separations technology and their impact on science and society.

THREE SESSION TRACKS AT HPLC 2016:

Technology: Better, Faster, Quantitative Separations

Interface to MS: Improving Information Content

BioAnalysis and Applications: Impacting Science and Society

Topics include column and stationary phase technology, interface to mass spectrometry,

microfluidic systems, capillary electrophoresis, LCxLC, QA&QC methods, QbD in separations,

and application to real world problems. A special emphasis in applications will be on

bioanalysis including:

10

pharmaceuticals, antibody-drug conjugates, antibody characterization, biotechnology,

proteins and proteomics, glycomics, metabolomics and lipidomics, food and nutrition, well-

characterized biologicals, biofuels, environment, and toxicology.

Also Featuring:

Tutorials, Short Courses, User Group Meetings, and Lunch Technical Sessions

For more information, visit: www.hplc2016.org

http://www.hplc2016.org/index.html

Type of Registration: Fees are posted under the "Online Registration" tab located at

www.HPLC2016.org.

Payment must be made by check or credit card payable in US Dollars and drawn on a US

bank (no bank wire transfers).

Registration is not accepted or acknowledged until payment is received.

By submitting this registration, you authorize the HPLC 2016 meeting to share your

information with attendees, etc.

Student Registrants: In order for the student rate to be accepted, must submit proof of

current full-time graduate or undergraduate, not postdoctoral, status at an academic

institution by providing both a copy of your Student I.D and a letter on university stationery

from your department chair along with the department chair contact details and email.

Email the letter and copy of the Student ID to janet@barrconferences.com.

All Oral and Poster Presenters: In order to present, the presenting author of each lecture

and poster must be registered as a conference attendee (not booth staff) and must

complete the registration process by paying online by April 18 to confirm intent to attend

and present at the meeting. If fees are not paid, submissions from that author will be

removed from the program.

Refund Policy: A processing fee of 20% will be collected on cancellations on or before April

1, 2016, after which the fees are non-refundable. Registration is transferable; must contact

Symposium Manager by no later than one week prior to the conference to transfer and

receive confirmation of the transfer of the registration (janet@barrconferences.com or

telephone 301-668-6001).

HPLC 2016 Symposium/Exhibit Manager

Ms. Janet Cunningham

Barr Enterprises

www.LinkedIn.com/in/BarrEnterprises

phone 301-668-6001

janet@barrconferences.com

www.HPLC2016.org

***********************************************************

JLABS, Tuesday Morning, June 21, 2016

Topic: “Swim with the Funds: The Story of Funding from Those Who Succeeded”

Speaker: Caleb Bell | CEO, Bell Biosystems

Colleen Cutcliffe | CEO and Co-founder, Whole Biome

Tim Hsiao | Small Business Innovation Specialist, NIH/NIAID

Casey Lynch | CEO and Co-founder, Cortexyme

[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners

Date and Time: Tuesday, June 21, 2016

10:00am | Registration and Networking

10:30am | Introduction

10:35am | Panel

11:30am | Q&A

11:45am | Lunch and Networking

12:30pm | Program Close

Location: LABS @ SSF, 329 Oyster Point Blvd , 3rd Floor, South San Francisco, CA

11

Fees: $20

Register at http://www.eventbrite.com/e/swim-with-the-funds-the-story-of-funding-from-

those-who-succeeded-tickets-25128996505?aff=blast

Topic Description Without it your startup will not float. There are many sources of funding including Angels, VC's, governments, incubators, Pharma, friends and family, etc... but how do you get it? What source(s) are best for your company?

Topics covered:

Johnson & Johnson Innovation, JLABS is fortunate to have a breath of startups with a wide

range of funding experience, so we asked them to share their inner funding thoughts and

secrets. Joins us for a deep dive to look how current startups are succeeding at the funding

game and how they plan to continue to keep their head above water.

• Where did you start?

• How does one offer effect interest form others?

• Angel vs. Friend/family vs. VC's vs. incubators

• Seed- series A, B, and beyond when is it best to have one investor lead the round?

• Do funding methods differ depending on the product: med

device/instrument,bioinformatics software, biologic drug or therapeutic.

• The process - how many times did you get up to the plate before you got on base?

How about non-accredited investors/crowd sourcing?

Speaker Bios

Caleb has served as CEO of Bell Biosystems since co-founding the company. Under

Caleb's leadership, Bell Biosystems has been recognized by the White House for its

"Breakthrough" in life science technologies, as a 2014 Rising Star by BayBio, and as

a "biotech on the cusp of something big" by the San Francisco Business Times. Caleb

sits on the board of trustees of BayBio and founded three companies prior to Bell

Biosystems, serving as CEO of one for six years. He is a well published scientist and

named inventor on multiple issued patents. Caleb earned a Ph.D. in Biophysical

Chemistry from Stanford University, completed the Stanford University Graduate

School of Business Ignite program, and received a B.S. in Biochemistry and Molecular

Biology from Penn State University.

Connect with Caleb:

Colleen Cutcliffe is the co-founder and CEO of Whole Biome, an early stage

microbiome company. Colleen has over a decade of experience managing and

directing fundamental biology research teams in the academic, pharmaceutical and

biotech sectors. Prior to starting Whole Biome, Colleen served as the Senior Manager

of Biology at Pacific Biosciences, a Scientist at Elan Pharmaceuticals and a

Postdoctoral Fellow at Chicago's Children's Memorial Hospital. Colleen received her

Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her

B.A. in Biochemistry from Wellesley College.

Connect with Colleen:

Tim manages various initiatives, including the I-Corps program at NIAID, to

strengthen the portfolio performance of federal investments in biomedical small

business innovation research/technology transfer (SBIR/STTR). He also conducts

portfolio analysis and leads a trans-NIH working group to help shape NIH's evaluation

metrics for SBIR/STTR commercialization success. He developed his expertise in

12

innovation policy and public-private partnership through his prior services as an

Innovation Policy Officer (Economic Section of the U.S. Embassy in Mexico City) and

a Science & Technology Policy Fellow (American Association for the Advancement of

Science). He holds a Ph.D. in Molecular Biophysics & Biochemistry from Yale

University, and is affiliated with NIAID Division of Extramural Research's Office of

Research Training and Special Programs (Contract-based).

Connect with Tim:

Casey Lynch is the co-founder and CEO of Cortexyme, a privately funded company

developing novel treatments and diagnostics for Alzheimer's disease and other

degenerative disorders. Casey was the co-founder and Managing Director of

NeuroInsights and Aspira Biosystems. Aspira was acquired by Nanomune Inc. in

2004. Casey oversaw toxicology screening and evaluated new product opportunities

at Centaur Pharmaceuticals where she established disease model testing paradigms

for multiple sclerosis, uveitis, and other neurological disorders. Casey conducted

primate preclinical trials for Alzheimer's disease treatment at the Wadsworth Medical

Center in Los Angeles and researched the neurological basis of schizophrenia and

epilepsy at UCLA. She has worked with companies on partnering and fundraising as

well as investors to identify and profit from opportunities in commercial neuroscience

through consulting, conferences, and publications. Casey has a BS in neuroscience

from UCLA, and an MS in neuroscience from UCSF doing research in the Mobley lab at

UCSF/ Stanford University where her graduate research focused on neurotrophic

factor cell biology and neurodegenerative diseases. She has completed the

Management Development for Entrepreneurs (MDE) program of the Anderson School

of Business. Casey is on the Board of Directors of The Neurotechnology Industry

Organization, a trade association for commercial neuroscience.

[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners

Laura Brege has over 25 years of executive management experience in the

pharmaceutical, biotechnology and venture capital industries. Most recently, Ms.

Brege was President & CEO of Nodality, Inc., a private company focused on

innovative personalized medicine approaches in oncology, immunology and immuno-

oncology. Prior to joining Nodality, Ms. Brege held several senior-level positions at

Onyx Pharmaceuticals, Inc., a global oncology company, including Executive Vice

President and Chief Operating Officer. While at Onyx, she led multiple functions,

including commercialization, strategic planning, corporate development, technical

operations and medical, scientific and government affairs. Prior to Onyx, Ms. Brege

was a General Partner at Red Rock Capital Management, a venture capital firm

investing in early stage technology companies. Previously Ms. Brege was CFO at COR

Therapeutics, helping build the company from an early stage R&D company through

commercial launch of a successful cardiovascular product. Earlier she served as CFO

at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege serves on the

Board of Directors of Acadia Pharmaceuticals, Aratana Therapeutics, Dynavax

Technologies, Portola Pharmaceuticals and Pacira Pharmaceuticals. She served on the

Board of California Life Sciences Association (CLSA). Ms. Brege received her MBA

from The University of Chicago and her undergraduate degree from Ohio University,

Honors Tutorial College.

***************************************************

CLSA, Lunch and Learn, Tuesday Mid Day, June 21, 2016

13

Topic: “Lunch & Learn: From Millennials to Gen X: What you need to know about Retirement

Plan Management”

Speakers: Mike Foy, CFP. DCIO Investment Specialist, Putnam Investments

And Michele Giangrande, Vice President, DCIO Consultant, T. Rowe Price Investments

Date and Time: Tuesday, June 21, 2016 from 11:00 AM to 1:00 PM (PDT)

Time/ Agenda:

• 11:00am | Registration

• 11:30am – 12:30pm | Program

• 12:30 – 1:00pm | Networking

Location: 250 East Grand Ave. , Suite 26 , South San Francisco, CA 94080South San Francisco, CA Top of Form

Ticket Information

Ticket Type Sales End Price Fee Quantity

CLSA Member

Membership status will be verified

upon registration.

Jun 21, 2016 Free $0.00 Ticket Quantity Select

Non-Member Jun 21, 2016 $75.00 $0.00 Ticket Quantity Select

Register at http://www.eventbrite.com/e/lunch-learn-from-millennials-to-gen-x-what-you-

need-to-know-about-retirement-plan-management-tickets-25362533019

Topic Description

Since the inception of the 401(k) in 1980, the responsibility of saving for retirement has

slowly shifted from employers to the employee. Coinciding with that shift has alsbeen a

change in the workforce from baby boomers to increasing numbers of millennials. This has

led to a retirement readiness crisis that affects all employees - from those employees about

to retire all the way to those starting their first jobs out of college.

Join UBS’s 401(k) advisors for lunch to gain insight on how to help you meet this retirement

challenge head on. Their knowledgeable team will cover important aspects of social security

to help soon-to-be retirees understand how to maximize monthly benefits in addition to

strategies and tactics to help put millennials on the path to retirement success.

*************************************************************************

3rd Annual Rosenman Institute, Wednesday Afternoon, June 22, 2016

Topic: “Medical Devices Reimagined":

Date and Time: Wednesday, June 22, 2016, 1:00 – 5:30 pm

Location: Byers Auditorium, Genentech Hall - 600 16th Street UCSF Mission Bay, San

Francisco, CA 94158

Fee: Free

Register at

https://www.eventbrite.com/orderconfirmation/24493653176/518462594/AA6ItQMgY

JABjLh5CpgacVHgWRuYtSsFoA/

Topic Description

Every day, engineers integrate new technology into medical devices. But with the

pace of advances in technology and discovery, the potential for devices now far

outstrips the state of the art. It is essential for us to reimagine the possibilities.

Where better to reimagine devices than the Rosenman Symposium, held at UCSF

14

Mission Bay? Together, we can speed the development of exciting technologies to

improve the lives of patients.

Check out the speaker lineup below!

Speaker Bios

Adam Gazzaley, M.D., Ph.D. is Professor in Neurology, Physiology and Psychiatry at

UC San Francisco, and the Founding Director of the Neuroscience Imaging Center,

Neuroscape Lab and the Gazzaley Lab. His lab explores mechanisms of neuroplasticity

and designs, develops and validates new technologies to optimize cognitive abilities

via engagement with closed-loop systems using custom-designed video games,

neurofeedback and transcranial electrical stimulation. Dr. Gazzaley is also co-founder

and Chief Science Advisor of Akili Interactive, a company developing therapeutic

video games and Chief Scientist of JAZZ Venture Partners, a venture capital firm

investing in experiential technology to improve human performance. He has filed

multiple patents based on his research, authored over 100 scientific articles, and

delivered over 450 invited presentations around the world. Dr. Gazzaley has received

many awards and honors, most recently the 2015 Society for Neuroscience – Science

Educator Award.

Since 1998, Hanson Gifford has been a Managing Member of The Foundry, LLC. The

Foundry has created Evalve (acquired by Abbott Labs), Concentric Medical (acquired

by Stryker), Emphasys Medical, First to File, Satiety, Xtent, Cierra Medical, Ardian

(acquired by Medtronic), Cabochon (acquired by Ulthera/Merz), Miramar Labs,

Twelve, Holaira, Cotera, and Fire1. Mr. Gifford is also a founder of ForSight Labs, an

ophthalmic device incubator which has started six companies. Prior to The Foundry,

Mr. Gifford was VP of Research and Development at Heartport, Inc. Mr. Gifford is an

inventor on over 225 issued U.S. patents. He has a B.S. in mechanical engineering

from Cornell University.

Darrell Johnson joined Medtronic in 2007 and serves as Vice President and General

Manager for the Cardiac Rhythm and Heart Failure (CRHF) Connected Care business.

Darrell has built an expertise in working within the medical device industry,

identifying how wireless technologies and data systems may be applied to improve

patient outcomes, decrease healthcare utilization costs, and increase provider care

delivery efficiencies. His passion centers on not simply bringing technologies to

market, but the successful implementation and utilization of these technologies

within the entire healthcare system, including patients.

Bryan Larson joined Stryker in 1997 and currently serves as the Vice President of

Product Excellence at the Endoscopy Division, located in the Silicon Valley. Bryan has

a strong passion for technology, people and teams. Through experiences in

manufacturing engineering, operations management, R&D, quality and regulatory

Bryan has built an expertise in solving tough user needs by driving innovation from

numerous sources and industries into the medical device arena. He received his BS in

Engineering Science from Montana Tech and MBA from Santa Clara University.

Ron Leuty has been a reporter or editor for more than 25 years, including editor of

two startup business journals and business editor of the Prague Post in the Czech

Republic. He has covered biotech for the San Francisco Business Times for nine

years. He also has covered banking, manufacturing, law and sports business.

15

Brian Otis, PhD is a CTO at Verily Life Sciences and a Research Associate Professor at

the University of Washington, Seattle. He received a B.S. in electrical engineering

from the University of Washington, Seattle, and a M.S. and Ph.D. degree in electrical

engineering from the University of California, Berkeley. He joined the faculty of the

University in 2005 where he founded a chip design research lab that develops tiny,

low power wireless chips for a variety of applications (neural recording, implantable

devices, wearable onbody wireless sensors, environmental monitoring, etc). He has

previously held positions at Intel Corporation and Agilent Technologies and has been

with Google Inc since 2012. He was a founder of Google [x]’s smart contact lens

project and leads the medical device efforts at Verily Life Sciences. He has served as

a member of the Technical Program Committee of the International SolidState

Circuits Conference (ISSCC) and Associate Editor of the Journal of Solid State Circuits

(JSSC). His research interests include low power SoC design, exploring limitations of

power and size of wireless systems, and the realization of novel biomedical devices.

Firat Yazicioglu, PhD, is the head of Neuromodulation Devices at GSK Bioelectronics

R&D and responsible for the development of implantable devices and creation of new

technologies for implantable devices. He received his PhD degree from KU Leuven in

Belgium and worked 13 years at imec, a Belgian technology research institute, where

he led the research on biomedical circuits and systems for wearable and implantable

applications. He has developed technologies for several biomedical devices including

wireless cardiac monitoring patches, wearable EEG recording headsets, and

implantable neural probes for high density recording of neural activity.

Reza Zadno, PhD is an Innovation Advisor to Novartis Venture Fund (NVF) located in

San Francisco, CA, USA. Reza is a serial entrepreneur focused on sourcing new

investments particularly in the area of medical devices. Reza was the founder,

President and CEO of Visiogen (a former NVF-portfolio company acquired by Abbott-

Medical Optics) and co-founder of PercuSurge (acquired by Medtronic). Reza is also

currently Executive in Residence at InterWest Partners. Prior to joining InterWest in

2012, Reza was a Venture Partner at New Leaf Venture Partners and, previously, an

Entrepreneur in Residence at Three Arch Partners. Earlier in his career, he was with

Cardiac Pathways (acquired by Boston Scientific) and with Raychem Corporation, now

Tyco. Reza holds a Ph.D. from Ecole des Mines de Paris and has filed more than 100

U.S. patents. He serves on the boards of the following non-NVF companies, Carbylan,

Gobiquity, Invuity, On Demand Therapeutics and Oraya Therapeutics.

***************************************************************

PBSS Workshop, Monday, June 27, 2016

Workshop

Topic: “UHPLC in Biopharmaceutical Analysis: Benefits, Practices, Issues and

Implementation”

Speakers: Dr. Michael W. Dong, MWD Consulting

Date and Time: Monday, June 27, 2016, 8:45-12:30

Registration fee (US$): (USD$)Regular: $125; For vendor-show reps: $25; For unemployed

& students: $20; For major-sponsor rep (incl lunch): $0;

Location: SF Bay Area: Foster City Crowne Plaza

Major Sponsor: (1)Agilent

Vendor show vendors registered to date:

Registration: http://www.PBSS.org

Registration deadline:6/23/2016 (it will close sooner if the seating cap is reached)

16

About the Topic

Ultra-high-pressure liquid chromatography (UHPLC) is the new standard HPLC platform

delivering higher performance with small-particle columns used on low-dispersion systems

with pressure limits of 15,000 – 23,000 psi. This intermediate-level 1/2-day training

workshop will provide a critical overview the fundamental concepts, benefits, potential

issues, and best practices of UHPLC in pharmaceutical analysis of small molecule drugs and

recombinant biologics (monoclonal antibodies, mAbs)

Who Should Attend

This workshop is intended for analysts, managers, and researchers wishing to have a

thorough understanding the fundamentals and practices of UHPLC in pharmaceutical

analysis. A basic knowledge of HPLC is assumed and some practical hands-on experience is

highly recommended.

Workshop Agenda

UHPLC 1: Concept and Benefits

1. Overview and perspectives, Glossary, the modern HPLC platform with higher

performance, UHPLC concepts (the need for high pressure, void volume, peak

volume, instrumental bandwidth), UV flow cell design, dwell volume.

2. Benefits and case studies: Very fast separations with good resolution, very high

resolution analysis of complex samples, facilitating rapid method development,

flexibility to customize resolution, a modernized generic method for most drugs, a

greener HPLC platform.

UHPLC 2: Potential Issues, Practices, and implementation

1. Potential issues and how to mitigate (viscous heating, operating nuances,

compatibility to existing methods, injection precision, detector sensitivity vs. mixing

volumes.

2. Method translation (transfer) issues: method portability, method conversion

(translation), “What is method transfer?”, need for partial method validation, case

studies.

3. How to transition from HPLC to UHPLC, end-fittings, system performance tradeoffs,

Myths in UHPLC, references.

Learning Outcomes UHPLC in Biopharmaceutical Analysis

The attendee will learn the benefits, best practices and potential issues of UHPLC in

pharmaceutical analysis including method translation and how to get started in UHPLC.

About the Speakers

Dr. Michael W. Dong is a principal consultant in MWD Consulting focusing on consulting and

training services on HPLC/UHPLC, pharmaceutical analysis and drug quality. He was

formerly Senior Scientist in Analytical Chemistry and Quality Control at Genentech,

Research Director at Synomics Pharma, Research Fellow at Purdue Pharma, and Senior Staff

Scientist at Applied Biosystems / Perkin-Elmer. He holds a Ph.D. in Analytical Chemistry

from the City University of New York, and a certificate in Biotechnology from U. C. Santa

Cruz. He has 100+ publications including a bestselling book on chromatography (Modern

HPLC for Practicing Scientists). He is an editorial advisory board member of LCGC magazine

and American Pharmaceutical Review.

*************************************************************

PBSS, Friday MidDay, July 29, 2016

Seminar luncheon

Topic: “CRISPR gene editing platform development for drug discovery and validation”

Speakers: Benjamin Haley, PhD (Genentech)

Organizers:

17

Date: Friday, July 29, 2016, 11:00-13:30

Registration fee (US$): (USD$);

Location: SF Bay Area: Foster City Crowne Plaza

Major Sponsor:

Vendor show vendors registered to date:

Registration: http://www.PBSS.org

Registration deadline:7/27/2016 (it will close sooner if the seating cap is reached)

******************************************************************

Bio2Device Group, Tuesday Evening, August 9, 2016

Topic: TBA

Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher

Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm

Date and Time: Tuesday, Oct. 13, 2015, 6:00pm

Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA

Cost:

$6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only

$20 - Late Registration and Non-Members

$25 - Walk-ins (as space permits)

Register at www.Bio2DeviceGroup.org

Speaker Bio

Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in

San Francisco and leads the company’s life sciences practice on the west coast of the

US. She joined the team in San Francisco in August 2012 after spending 5 years in

Simon-Kucher’s Boston office.

In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-

to-customer, market entry strategies, pricing and market access strategies, innovative

pricing strategies, product lifecycle strategies, licensing and valuation, market

forecasting and value communication, including global value story development and

implementation. She is a trusted advisor of leading pharmaceutical and biotech

companies across a wide range of therapeutic areas in all major healthcare markets

across the globe.

Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from

Yale University and a B.A. in Physics with honors from Wellesley College where she was

a Goldwater Scholar and a Schiff Fellow.

She is the author and coauthor of several scientific publications and has research

experience in theoretical and experimental physics, biophysics, cell biology, cancer

biology, genomics, proteomics, bioinformatics and biochemistry.

****************************************************************

JLABS Meet with…Path, Thursday Morning, Sept. 8, 2016

Event: Meet with Path

PATH Participating Representative:

David Shoultz, Ph.D., MS, MBA | Global Program Leader, Drug Development and

Devices and Tools, PATH

Date and Time: Thursday, September 8, 2016 from 10:30 AM to 1:00 PM (PDT)

Agenda:

10:30am | Registration Opens and Networking

11:00am | Presentation and Q&A

11:45am | Networking Lunch

18

1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be

approved. The application period ends on August 3rd.

Fees:

Presentation

$25 | General Public

$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of

one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and

lunch will remain open until noon on September 7th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-

one application period ends on August 3rd. Your application will be reviewed and you

will be notified of acceptance on August 19th. Acceptance of one-on-one meetings is

not guaranteed as all applications must be approved.

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd., 3rd Floor,

South San Francisco, CA

Register at http://www.eventbrite.com/e/meet-with-path-tickets-

23921043485?aff=weekly

Description of PATH

PATH is the leader in global health innovation. An international nonprofit

organization, PATH saves lives and improves health, especially among women and

children. PATH accelerates innovation across five platforms - vaccines, drugs,

diagnostics, devices, and system and service innovations - that harness their

entrepreneurial insight, scientific and public health expertise, and passion for health

equity. By mobilizing partners around the world, PATH takes innovation to scale,

working alongside countries primarily in Africa and Asia to tackle their greatest

health needs.

PATH works with companies to create market-based solutions through tailored

partnership opportunities that deliver measurable impact. PATH matches each

company's resources and expertise with their unique strengths to accelerate the next

generation of lifesaving innovations, creating better health and opportunity for all.

Partnering with PATH is a smart investment that can yield significant social impact.

Companies choose to work with PATH because of their:

Focus on high-impact, large-scale, sustainable approaches - and measurable results.

Proven technical and market expertise.

History of successful partnership with the private sector that dates from their

founding in 1977.

Extensive in-country networks in more than 70 countries around the world.

International reputation as a trusted and influential convener and translator and their

ability to mobilize partners across borders, sectors, and disciplines.

Major funders include the Bill & Melinda Gates Foundation; the US government; other

governments, other nonprofit organizations, and multilateral agencies such as the

World Health Organization; individuals; and interest from investments.

19

Headquartered in Seattle, Washington, PATH has 1,300 employees, 1,400 partners

worldwide, and an annual budget of US$300 million. Visit www.path.org for more

details. If your company has technologies with applications in low- and middle-

income countries, apply to meet one-on-one with PATH.

Dr. David Shoultz, program leader, Drug Development and Devices and Tools

programs at PATH, will be in attendance on Thursday, September 8, to provide an

overview presentation on PATH's areas of interest and keys to solving global health

issues.

David and other PATH representatives will meet with a handful of preapproved

applicants after the presentation. To be considered for a one-on-one meeting,

complete the information required here.

Speaker Bio

David Shoultz, Ph.D., MS, MBA, directs two of PATH's product development

programs: the Drug Development program, which seeks to discover, develop, and

deliver safe, effective, and affordable treatments for neglected diseases, and the

Devices and Tools program, which focuses on advancing appropriate, affordable, and

accessible technologies to improve the health of underserved populations.

Prior to joining PATH in 2014, Dr. Shoultz served as the director of grantee and

partner engagement and as a member of the leadership team at the Bill & Melinda

Gates Foundation. In this role, he led an effort to strengthen the foundation's

relationships with its partner organizations to facilitate ongoing interactions and help

achieve maximum impact. Previously, he served as a deputy director in the

foundation's Global Health Program, Infectious Disease, where he was central to

strategy, planning, and management for four strategic program teams, including

malaria, enteric diseases, pneumonia, and the neglected tropical diseases.

Prior to his roles at the foundation, Dr. Shoultz worked as a member of the senior

management team for a number of clinical research organizations participating in the

development of new medicines, including PPD Development, PRA International, and

Biomedical Systems. He has been a member of the affiliate faculty for the

departments of Global Health and Epidemiology at the University of Washington since

2000 and sits on the board of the Geneva Foundation, where he also serves as the

inaugural chair of the Scientific Advisory Committee. Dr. Shoultz earned his Ph.D.

and MS from the School of Public Health and Community Medicine at the University of

Washington, where he also obtained his BSN. He holds an MBA from the Albers

School of Business and Economics at Seattle University, where he is a faculty

member in the Executive MBA Program.

David Shoultz leads our work in drug development and in devices and tools.